You are here: Industry Insights > LDL-C

News List

More Aggressive Tx Needed for Familial Hypercholesterolemia drugs
September 24, 2019
Even with care in specialty clinics, low-density lipoprotein cholesterol (LDL-C) persists above target levels in more than half of patients with familial hypercholesterolemia (FH) ...
Higher LDL-C Levels Linked to Early-Onset Alzheimer Disease drugs
June 03, 2019
Higher LDL-C Levels Linked to Early-Onset Alzheimer Disease.
Daiichi Sankyo Europe, Esperion Announce Validation of MAA for Bempedoic Acid and the Bempedoic Acid/Ezetimibe Fixed Dose Combination Tablet americanpharmaceuticalreview
March 01, 2019
Daiichi Sankyo Europe and Esperion Therapeutics announced the validation of the Marketing Authorisation Application (MAA) for bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet by the European Medicines Agency (EMA).
Amgen receives NMPA approval for Repatha in China biospectrumasia
January 29, 2019
Repatha is an innovative biologic medicine proven to effectively lower LDL-C
Amgen's Repatha shows durable treatment effect in long-term study biospectrumasia
December 03, 2018
The results of all analyses were presented at the American Heart Association's Scientific Sessions 2018 in Chicago.
Quest Diagnostics moves to more accurate, nonfasting cholesterol tests biospectrumasia
September 12, 2017
Quest Diagnostics is the first national laboratory provider in the United States to enable accurate nonfasting lipid testing using the novel method in patient testing
Landmark outcomes study shows that Repatha decreases LDL-C to unprecedented low levels cphi-online
March 20, 2017
Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha.

Previous page 1 2 Next page